Asymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol
Chronic kidney disease is a major public health problem. In the last decade, it has been shown that the early stages of chronic kidney disease are associated with an inflammatory condition involving an increased risk of cardiovascular morbidity and long-term mortality. In patients with chronic kidne...
Main Authors: | Elena Oliva-Damaso, Nestor Oliva-Damaso, Francisco Rodriguez-Esparragon, Juan Payan, Alberto Marañes, Yanet Parodis, Lopez Eduardo Baamonde-Laborda, Nicanor Vega Diaz, Jose Carlos Rodriguez-Perez |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-03-01
|
Series: | Kidney International Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024916301474 |
Similar Items
-
Asymmetric (ADMA) and Symmetric (SDMA) Dimethylarginines in Chronic Kidney Disease: A Clinical Approach
by: Elena Oliva-Damaso, et al.
Published: (2019-07-01) -
Comparison of Paricalcitol (I.V) and Alfacalcidol (I.V) in Treatment of Secondary Hyperparathyroidism (SHPT) in Hemodialysis Patients
by: Mansoor Abbas Qaisar, et al.
Published: (2020-12-01) -
Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis
by: Liu Y, et al.
Published: (2019-03-01) -
Non-Compliance of Hemodialysis and Related Factors among End-Stage Renal Disease Patients
by: Wijan Lal, et al.
Published: (2019-12-01) -
Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA)
by: You‐Lin Tain, et al.
Published: (2017-03-01)